Koshinski Asset Management Inc. increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 60.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,328 shares of the pharmaceutical company’s stock after buying an additional 879 shares during the period. Koshinski Asset Management Inc.’s holdings in Vertex Pharmaceuticals were worth $676,000 at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in the business. Roman Butler Fullerton & Co. grew its position in shares of Vertex Pharmaceuticals by 0.9% during the second quarter. Roman Butler Fullerton & Co. now owns 4,345 shares of the pharmaceutical company’s stock worth $1,261,000 after buying an additional 38 shares in the last quarter. Eudaimonia Partners LLC grew its holdings in Vertex Pharmaceuticals by 12.7% during the 1st quarter. Eudaimonia Partners LLC now owns 354 shares of the pharmaceutical company’s stock worth $84,000 after acquiring an additional 40 shares in the last quarter. 1776 Wealth LLC increased its position in shares of Vertex Pharmaceuticals by 26.6% in the 1st quarter. 1776 Wealth LLC now owns 195 shares of the pharmaceutical company’s stock valued at $46,000 after purchasing an additional 41 shares during the last quarter. Baystate Wealth Management LLC raised its holdings in shares of Vertex Pharmaceuticals by 37.3% in the 2nd quarter. Baystate Wealth Management LLC now owns 151 shares of the pharmaceutical company’s stock valued at $44,000 after purchasing an additional 41 shares in the last quarter. Finally, Fulton Breakefield Broenniman LLC lifted its position in shares of Vertex Pharmaceuticals by 1.7% during the 1st quarter. Fulton Breakefield Broenniman LLC now owns 2,696 shares of the pharmaceutical company’s stock worth $642,000 after purchasing an additional 45 shares during the last quarter. Institutional investors own 93.42% of the company’s stock.
A number of analysts have weighed in on the company. Stifel Nicolaus raised their price target on Vertex Pharmaceuticals from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Cfra boosted their target price on Vertex Pharmaceuticals from $286.00 to $297.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Royal Bank of Canada downgraded Vertex Pharmaceuticals from an “outperform” rating to a “sector perform” rating and upped their price target for the company from $250.00 to $260.00 in a report on Tuesday, April 28th. They noted that the move was a valuation call. Piper Sandler raised their price objective on shares of Vertex Pharmaceuticals from $302.00 to $327.00 and gave the stock an “overweight” rating in a report on Friday. Finally, SVB Leerink upped their target price on shares of Vertex Pharmaceuticals from $263.00 to $274.00 and gave the company a “market perform” rating in a report on Friday. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the company. Vertex Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $295.81.
Shares of NASDAQ VRTX opened at $272.00 on Friday. The stock has a fifty day moving average price of $287.06 and a 200 day moving average price of $257.51. Vertex Pharmaceuticals Incorporated has a 1-year low of $165.23 and a 1-year high of $306.08. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.54 and a quick ratio of 3.42. The company has a market cap of $70.52 billion, a PE ratio of 39.53, a P/E/G ratio of 1.31 and a beta of 0.94.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Thursday, July 30th. The pharmaceutical company reported $2.61 EPS for the quarter, topping the Zacks’ consensus estimate of $1.75 by $0.86. The company had revenue of $1.52 billion during the quarter, compared to the consensus estimate of $1.41 billion. Vertex Pharmaceuticals had a net margin of 38.51% and a return on equity of 30.45%. Analysts anticipate that Vertex Pharmaceuticals Incorporated will post 7.6 earnings per share for the current fiscal year.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
See Also: How to Invest in Growth Stocks
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.